Please Wait
Applying Filters...
Digital Content 
NEWS #PharmaBuzz
02 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/kyowa-kirin-announces-acceptance-of-abstract-for-presentation-at-the-association-for-research-in-vision-and-ophthalmology-annual-meeting-2024-302106101.html
06 Feb 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/kyowa-kirin-announces-first-patient-enrolled-in-the-phase-2-clinical-trial-evaluating-tivozanib-eye-drops-in-patients-with-diabetic-macular-edema-302054044.html
27 Jun 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/aveo-oncology-announces-completion-of-enrollment-in-pivotal-phase-3-tinivo-2-study-of-fotivda-tivozanib-in-combination-with-opdivo-nivolumab-in-advanced-renal-cell-carcinoma-301864465.html
12 Oct 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/10/12/2533371/0/en/U-S-Patent-Trademark-Office-Allows-AVEO-Oncology-s-Patent-Application-Covering-Use-of-FOTIVDA-for-the-Treatment-of-Refractory-Advanced-Renal-Cell-Carcinoma.html
06 Jun 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/06/06/2456662/0/en/AVEO-Oncology-Presents-Three-Posters-for-Tivozanib-at-the-2022-ASCO-Annual-Meeting.html
14 Feb 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/02/14/2384775/0/en/AVEO-Oncology-to-Present-Positive-New-Long-Term-PFS-Data-from-Phase-3-TIVO-3-Study-of-FOTIVDA-tivozanib-in-Third-and-Fourth-Line-Renal-Cell-Carcinoma.html
LOOKING FOR A SUPPLIER?
Market Place
Share